Even with disease-modifying therapies, patients who have chronically active inflammatory MS lesions can expect an aggressive disease course and poor outcomes. A new study shows that patients with ≥4 ...

A phase 3 clinical trial tested the safety and efficacy of teriflunomide, an oral immunomodulatory drug, in children with multiple sclerosis. Although the medication did not prevent disease relapses ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.

Tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, reduced new, active brain lesions in people with relapsing multiple sclerosis (MS), a phase IIb dose-finding trial showed. After 12 weeks of ...

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients. Ibudilast intervention in patients with progressive multiple ...

Multiple sclerosis (MS) is a chronic, inflammatory autoimmune disease that affects the central nervous system (the brain and spinal cord). In MS, the immune system attacks the protective covering ...

Please provide your email address to receive an email when new articles are posted on . Two studies included 1,367 patients with MS who were given continuous Kesimpta or switched to Kesimpta. Kesimpta ...

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

Advanced MRI techniques can differentiate between degenerative and reparative processes in MS lesions, offering insights into disease progression. Quantitative MRI (qMRI) provides detailed biophysical ...